Lonza adds early-phase bio-production service

Big contract manufacturer Lonza is backtracking in the drug product lifecycle to expand its franchise. The Swiss company has launched a process development and material supply service designed for the discovery and early development market.

The move is further evidence of what appears to be a trend in the making of CMOs expanding to become CDMOs, adding drug development services to their manufacturing offerings. It's not a particularly new concept, but one that is becoming more common.

The Lonza service is called Light Path. It involves the production of milligram to kilogram quantities of biologics--mammalian- and microorganism-based. Its target is drugmakers at the early stages of development, a long way from the company's sweet spot of making APIs and finished drug products.

Yet the service offering fits with the company's intent to provide services spanning R&D through finished product manufacturing.

Light Path is available at Lonza's biologics development sites in Slough and Cambridge, U.K.; Hopkinton, MA; Tuas, Singapore; and Visp, Switzerland.

- here's the story
- see the Lonza announcement

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.